RxDoctor Payments Data

Gary Matthews, MD

Psychiatry · Washington, DCNPI 1689018772

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations.

$1,040in general payments, 2019–2025

Across 62 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$232
  • Takeda Pharmaceuticals U.S.A., Inc.$145
  • Johnson & Johnson$123
  • Otsuka America Pharmaceutical, Inc.$112
  • Lundbeck LLC$102
  • Shire North American Group Inc$68
  • plus $258 from 8 others

What the payments were for

  • Food & beverage$1,040100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,040 in reported general payments places this provider in the 80th percentile of 226 psychiatry providers in District of Columbia.

See all psychiatry providers in District of Columbia

Medicare billing

Part B allowed, 2024
$42,953
Medicare patients
50
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide21$17,130
BelsomraSuvorexant13$5,313
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine154$4,445
Aripiprazole60$4,432
Bupropion XlBupropion Hcl146$3,642
Duloxetine Hcl114$3,242
Trazodone Hcl253$3,142
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine52$2,945
Lurasidone Hcl26$2,776
Buspirone Hcl143$2,319
Quetiapine Fumarate145$2,077
Hydroxyzine Hcl88$1,976
Doxepin Hcl39$1,835
Atomoxetine Hcl15$1,593
Oxcarbazepine24$1,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$145$17,13021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 226 psychiatry providers in District of Columbia.

Other psychiatry in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →